Successful Treatment for Hypercalcemia due to Cosecretion of Parathyroid Hormone-Related Protein and 1,25-Dihydroxyvitamin D3 in Non-Small-Cell Lung Cancer: A Case Report and Literature Review

Takunori Ogawa; Jun Miyata; Koichi Fukunaga; Akihiko Kawana; Takashi Inoue

doi:10.1155/2020/2475725

Successful Treatment for Hypercalcemia due to Cosecretion of Parathyroid Hormone-Related Protein and 1,25-Dihydroxyvitamin D₃ in Non-Small-Cell Lung Cancer: A Case Report and Literature Review

Case Rep Pulmonol. 2020 Jan 3:2020:2475725. doi: 10.1155/2020/2475725. eCollection 2020.

Authors

Takunori Ogawa¹, Jun Miyata², Koichi Fukunaga¹, Akihiko Kawana², Takashi Inoue³

Affiliations

¹ Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
² Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
³ Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan.

Abstract

Hypercalcemia of malignancy frequently manifests as paraneoplastic syndrome in patients with solid tumors. A 71-year-old man was diagnosed with stage IIIB lung squamous cell carcinoma. Laboratory examination revealed high serum calcium concentration with elevated serum parathyroid hormone-related protein (PTHrP) and 1,25-dihydroxyvitamin D₃ levels. As the patient did not respond to the initial treatment with calcitonin, extracellular fluid infusion, and chemotherapy, systemic prednisolone was administered additionally. Thus, the levels of serum calcium normalized and PTHrP and 1,25-dihydroxyvitamin D₃ decreased simultaneously. To our knowledge, this is the first case report on the successful treatment of hypercalcemia of malignancy caused by PTHrP and 1,25-dihydroxyvitamin D₃ cosecretion in a patient with lung cancer.

Publication types

Case Reports